Eclat Pharmaceuticals Overview

  • Founded
  • 2011
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $50.9M
Latest Deal Amount

Eclat Pharmaceuticals General Information


Operator of a specialty pharmaceutical company. The company is focused on the development, approval and commercialization of niche medicine brands and other generic products. The company's product, Hycet is an oral solution that contains hydrocodone bitartrate, an opioid agonist for pain relief to patients above 2 years of age.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Delivery
Primary Office
  • 699 Trade Center Boulverd
  • Suite A
  • Chesterfield, MO 63005
  • United States
+1 (636) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eclat Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 13-Mar-2012 $50.9M 000.00 000.00 Completed Startup
1. Seed Round 01-Jan-2011 000.00 000.00 Completed Startup
To view Eclat Pharmaceuticals’s complete valuation and funding history, request access »

Eclat Pharmaceuticals Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Deerfield Management Venture Capital Minority 000 0000 000000 0
To view Eclat Pharmaceuticals’s complete investors history, request access »